Q3 2025 · 13F-HR
Foresite Capital Management IV, LLCholdings as filed
Filed 2025-11-14 · accession 0001104659-25-112500
$182.6M
Reported value
6
Positions
2025-09-30
Period end
The Brief · Foresite Capital Management IV, LLC · Q3 2025
AI · grounded in 13F
Foresite Capital Management IV, LLC established a new position in CYTK valued at $25.19M. The fund closed its entire position in KURA, reducing exposure by $4.71M. Additionally, the manager trimmed its holding in MAZE by 75.25% and increased its stake in Pharvaris N.V. by 8.34%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | Pharvaris N.V. | $119.2M | 65.3% | 4,778,581 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $25.2M | 13.8% | 458,295 | Common | SOLE |
| 578784100 | MAZE | Maze Therapeutics, Inc. | $13.6M | 7.42% | 522,657 | Common | SOLE |
| 55083R203 | LYEL | Lyell Immunopharma, Inc. | $13.0M | 7.12% | 800,399 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $6.4M | 3.52% | 160,000 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $5.2M | 2.86% | 1,000,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.